Protease inhibitor-sparing regimens: New evidence strengthens position

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue SUPPL. 1, 2003, Pages

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANXIETY DISORDER; ARTHRALGIA; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LIVER FAILURE; LIVER TOXICITY; MYALGIA; PRIORITY JOURNAL; RASH; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; URTICARIA; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOLS; CLINICAL TRIALS; COHORT STUDIES; DELAVIRDINE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNOSUPPRESSION; MUTATION; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0037741309     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288: 222-35.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
4. Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999;20:299-321.
5. Moyle GJ. Protease inhibitor-sparing HAART: a review of key studies. Infect Med 2000;17:442-55.
6. Moyle GJ, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Read 2000;10:479-85.
7. Moyle GJ. Wilkins E, Leen C, et al. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use. AIDS 2000; 14:1453-4.
8. Erickson JW, Burt SK. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 1996;36:545-71.
9. D'Aquila RT. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring. Clin Lab Med 1994;14:393-422.
10. Arnold E, Ding J, Hughes SH, et al. Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates. Curr Opin Struct Biol 1995;5:27-38.
11. Jeffrey S, Baker D, Tritch R, et al. A resistance and cross-resistance profile for Sustiva™ (efavirenz, DMP 266) [abstract 702]. Presented at the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
12. Sustiva [package insert]. Princeton, NJ: Bristol Myers Squibb; 2002. www.sustiva.com.
13. Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2002. www.viramune.com.
14. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [abstract 176]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
15. Keiser P, Nassar N, White C, et al. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002;3:296-303.
16. Martinez E, Podzamczer D, Ribera E, et al. Switching protease inhibitors to nevirapine (NEV), efavirenz (EFA) or abacavir (ABA): a randomized, multicenter, open-label, simplification trial [abstract WeOrB1262]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
17. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15: 2385-95.
18. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002;16:53-61.
19. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-9.
20. Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/(μL and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). AIDS 2002;16:1554-6.
21. Pulido F, Arribas JR, Miro JM, et al. Comparative study of efavirenz or protease inhibitor-based HAART in HIV-infected, antiretroviral naive patients with <100 CD4 cell/(μL and opportunistic diseases (EFAVIP-2 study) [abstract TuOrB1187]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
22. Pollard R, and the 1090 Team. Factors predictive of durable HIV suppression in randomized double blind trial with nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) in treatment-naïve (ARV-n) patients with advanced AIDS [poster]. Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 2, 2000.
23. Wit FW, Wood R, Horban A, et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001;15:2423-9.
24. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-45.
25. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998;12:F197-202.
26. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults. A randomized equivalence trial. JAMA 2001;285:1155-63.
27. Barner A, Myers M. Nevirapine and rashes. Lancet 1998;351: 1133.
28. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999;13:999-1000.
29. Bartlett JA, Johnson J, Herrera G, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001(CLASS) preliminary 48-week results [abstract TuOrB1189]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
30. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341: 1865-73.
31. Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001;345:398-407.
32. Robbins G, Shafer R, Smeaton L, et al. Study of initial antiretroviral strategies for the treatment of HIV infection: a randomized 6-arm trial utilizing a factorial design [abstracts LbOr20A and LbOr20B]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002,
33. Squires K. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor-sparing anti-retroviral strategies versus a standard PI-containing regimen, final 48-week data [abstract LbPeB7046]. Presented at the XIII International AIDS Conference, Durban, South Africa, July 9-14, 2000.
34. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002;7:81-90.
35. Montaner JSG, Saag M, Barylski C. FOCUS study: saquinavir QD regimen versus efavirenz QD regimen 24-week analysis in HIV infected patients [oral presentation 1-670]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 16-19, 2001.